News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aegerion Pharmaceuticals, Inc. (AEGR) Presents Data From Phase 3 Extension Study Of JUXTAPID™ (Lomitapide) Capsules In Homozygous Familial Hypercholesterolemia (Hofh) At American Heart Association Scientific Sessions


11/18/2013 12:45:46 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., Nov. 18, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development and commercialization of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases, today presented data from its open-label Phase 3 extension study of JUXTAPID™ (lomitapide) capsules in patients with homozygous familial hypercholesterolemia (HoFH). The data were presented in a poster at the American Heart Association's Scientific Sessions taking place in Dallas.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES